01 Increasing Adoption of Longer-Acting Anti-VEGF Therapies The anti-VEGF therapeutics market is increasingly focused on treatments designed to extend dosing intervals and reduce the frequency of intravitreal injections. Longer-acting therapies can help reduce the treatment burden associated with chronic retinal diseases while supporting sustained disease management. Pharmaceutical companies are therefore continuing to develop formulations and delivery approaches intended to provide longer-lasting therapeutic effects. In February 2025, pharmaceutical companies continued advancing longer-duration treatment approaches for retinal diseases requiring ongoing anti-VEGF therapy.
02 Growing Development of Biosimilars in Ophthalmology The availability and development of biosimilar anti-VEGF therapies are becoming increasingly important within the ophthalmology market. Biosimilars can increase treatment options and potentially improve access by introducing additional competition into established therapeutic categories. Their growing presence is contributing to changes in pricing strategies and competitive dynamics among manufacturers of retinal disease treatments. In August 2025, continued development and commercialization activities involving ophthalmic biosimilars supported greater competition within the retinal therapeutics landscape.
01 Rising Prevalence of Retinal and Vision-Threatening Diseases The increasing burden of conditions such as age-related macular degeneration, diabetic macular edema, and other retinal vascular diseases is supporting demand for anti-VEGF therapeutics. Aging populations and the growing prevalence of diabetes are contributing to the number of patients requiring diagnosis and long-term retinal disease management. This expanding patient population provides a fundamental driver for anti-VEGF treatment demand.
01 High Treatment Costs and Financial Burden of Long-Term Therapy Anti-VEGF treatment can involve substantial costs because many retinal diseases require repeated administration and ongoing clinical monitoring. The cumulative financial burden can create access challenges for patients and healthcare systems, particularly where reimbursement coverage is limited. High treatment costs therefore remain a significant factor affecting the accessibility of certain branded anti-VEGF therapies.
01 Expansion of Anti-VEGF Treatment Access in Emerging Healthcare Markets Growing investment in ophthalmology infrastructure and specialized eye-care services creates opportunities for expanding access to anti-VEGF therapeutics in emerging markets. Improvements in diagnostic capabilities, retinal clinics, and healthcare professional training can enable more patients to receive treatment for vision-threatening diseases. The expansion of specialized eye-care capacity therefore represents an important growth opportunity.
01 Maintaining Patient Adherence to Repeated Treatment and Monitoring Many anti-VEGF therapies require patients to attend regular clinical appointments for injections and disease monitoring. Frequent visits can create logistical, financial, and physical challenges, particularly for elderly patients and those living far from specialized eye-care facilities. Maintaining long-term adherence to treatment schedules remains a significant challenge for healthcare providers and the anti-VEGF therapeutics market.
June 2026 Regeneron Pharmaceuticals expanded its ophthalmology therapeutics portfolio by advancing next-generation anti-VEGF treatments designed for retinal diseases, including age-related macular degeneration and diabetic eye disorders. The company focused on improving treatment durability, reducing dosing frequency, and enhancing patient outcomes through innovative biologic therapies.
April 2026 Roche expanded its ophthalmology portfolio by advancing anti-VEGF therapeutic solutions featuring longer-acting formulations and improved delivery approaches for retinal conditions. The company focused on developing treatments that provide sustained disease control and improve convenience for patients requiring repeated injections.
January 2026 Novartis expanded its retinal disease treatment portfolio by strengthening its anti-VEGF therapy development programs focused on improving efficacy, extending treatment intervals, and supporting personalized approaches for patients with retinal vascular disorders.
October 2025 Bayer expanded its ophthalmology portfolio by advancing anti-VEGF treatment solutions for retinal diseases. The company focused on improving therapeutic effectiveness, expanding patient access, and developing innovative approaches for vision preservation.